We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.39M
AUM Growth
-$132K
Cap. Flow
+$358M
Cap. Flow %
6,649.45%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$44.9M
3
ABBV icon
AbbVie
ABBV
+$28.7M
4
VTYX
Ventyx Biosciences
VTYX
+$23.6M
5
PCVX icon
Vaxcyte
PCVX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
126
Spyre Therapeutics
SYRE
$8.5B
$945 0.02%
71,889
– –
VOR icon
127
Vor Biopharma
VOR
$1.06B
$445 0.01%
5,590
-36,077
-87% -$3.55M
LBPH
128
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$422 0.01%
113,500
– –
ABCL icon
129
CALL
AbCellera Biologics
ABCL
$1.65B
– –
-250,000
Closed -$2.66K
AMGN icon
130
Amgen
AMGN
$209B
– –
-57,100
Closed -$13.9K
CLDX icon
131
Celldex Therapeutics
CLDX
$2.94B
– –
-112,700
Closed -$3.04K
CTMX icon
132
CytomX Therapeutics
CTMX
$690M
– –
-2,124,975
Closed -$3.89K
ERAS icon
133
Erasca
ERAS
$6.15B
– –
-1,667,693
Closed -$9.29K
GH icon
134
CALL
Guardant Health
GH
$19.1B
– –
-50,000
Closed -$2.02K
GILD icon
135
Gilead Sciences
GILD
$165B
– –
-287,600
Closed -$17.8K
IMCR icon
136
Immunocore
IMCR
$1.7B
– –
-131,100
Closed -$4.89K
MIST icon
137
Milestone Pharmaceuticals
MIST
$129M
– –
-1,817,521
Closed -$11.2K
NTRA icon
138
CALL
Natera
NTRA
$36.4B
– –
-150,000
Closed -$5.32K
NVAX icon
139
CALL
Novavax
NVAX
$1.21B
– –
-75,000
Closed -$3.86K
REGN icon
140
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-22,200
Closed -$13.1K
SGHT icon
141
Sight Sciences
SGHT
$291M
– –
-200,000
Closed -$1.8K
TBPH icon
142
Theravance Biopharma
TBPH
$873M
– –
-1,370,250
Closed -$12.4K
TRML
143
DELISTED
Tourmaline Bio
TRML
– –
-23,600
Closed -$1.06K
VTGN icon
144
VistaGen Therapeutics
VTGN
$9.98M
– –
-447,376
Closed -$11.8K
SONX
145
DELISTED
Sonendo, Inc.
SONX
– –
-723,478
Closed -$1.24K
NMTR
146
DELISTED
9 Meters Biopharma
NMTR
– –
-425,286
Closed -$2.22K
ISEE
147
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,361,400
Closed -$13.1K
APTX
148
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-538,500
Closed -$300
SGFY
149
DELISTED
Signify Health, Inc.
SGFY
– –
-900,000
Closed -$12.4K
GBT
150
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-2,044,000
Closed -$65.3K
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39M, down 2.4% from $5.52M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed deployed $358M of net new capital in Q3 2022, opening 15 new positions and adding to 31 existing holdings. Its largest new stake was Third Harmonic Bio: 5,779,071 shares worth $110K.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $81.3M trimmed.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110K.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168K.
  • OrbiMed's ten largest holdings make up 31% of its $5.39M portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39M.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.